Literature DB >> 1818389

Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report.

D Bunnag1, C Viravan, S Looareesuwan, J Karbwang, T Harinasuta.   

Abstract

A 5-day course of oral artesunate at total doses of 1200, 600, 650 mg and intramuscular artemether 480 mg proved effective (90-100% cured) in the treatment of multidrug resistant falciparum malaria in Thailand. Shorter courses yielded high recrudescence rates. The fever clearance and parasite clearance times were short. The side effects were mild and transient including occasional abnormal electrocardiograms and pain at the injection site. Slight reduction of neutrophil leucocytes and reticulocytes was observed. Further studies of artesunate and artemether should be carried out to find the optimum dosage regimen and to clarify the hematological effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818389

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  28 in total

1.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar.

Authors:  T Shwe; M Lwin; S Aung
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 3.  Origin and Spread of Evolving Artemisinin-Resistant Plasmodium falciparum Malarial Parasites in Southeast Asia.

Authors:  Matthew R Hassett; Paul D Roepe
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

4.  Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria.

Authors:  K Na Bangchang; J Karbwang; C G Thomas; A Thanavibul; K Sukontason; S A Ward; G Edwards
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 5.  Artemisinin derivatives for treating uncomplicated malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria.

Authors:  S Looareesuwan; B Oosterhuis; B M Schilizzi; F A E Sollie; P Wilairatana; S Krudsood; Ch B Lugt; P A M Peeters; J O Peggins
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

7.  Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Suparp Vannaphan; Sombat Treeprasertsuk; Udomsak Silachamroon; Weerapong Phomrattanaprapin; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-03       Impact factor: 0.267

8.  Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand.

Authors:  S Krudsood; K Chalermrut; C Pengruksa; S Srivilairit; U Silachamroon; S Treeprasertsuk; S Kano; G M Brittenham; S Looareesuwan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-06       Impact factor: 0.267

9.  Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.

Authors:  J Karbwang; K Na-Bangchang; A Thanavibul; D Bunnag; T Chongsuphajaisiddhi; T Harinasuta
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

10.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.

Authors:  Gilbert Lefèvre; Polly Carpenter; Claire Souppart; Heinz Schmidli; Mark McClean; Daria Stypinski
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.